Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Your cancer must be measurable on a CT scan and/or MRI scan using specific medical measurement standards.
• You may be eligible if you have skin melanoma (cutaneous melanoma) that cannot be surgically removed or has spread to other parts of the body, and your cancer has continued to grow despite previous treatments with certain immunotherapy drugs.
• If your melanoma has a specific gene change called a BRAF mutation, you must either be unable to take, or have chosen not to take, a specific type of targeted treatment (BRAF+MEK inhibitor).
• You may be eligible if you have a type of lung cancer (NSCLC) that cannot be removed by surgery, has spread, tests positive for a marker called PD-L1, does not have certain specific gene changes (EGFR or ALK), and has gotten worse during or after treatment with certain immunotherapy drugs.
• Your cancer must have shown clear signs of growing on scans at least 4 weeks before starting the study drug (confirm with trial site if this requirement may be flexible in your case).
• A blood marker called LDH must be at or below a certain level (2.5 times the upper limit of normal) — your doctor can check this with a blood test.
• If you are a woman who could become pregnant, you must have a negative pregnancy test within 72 hours before starting the study drug.
• Women who could become pregnant must be willing to use two forms of birth control throughout the study and for 60 days (or 5 months if receiving a drug called nivolumab) after the last dose.
• Male patients whose partners could become pregnant must use barrier contraception from the time they agree to join the study until 60 days after finishing the study drug, and must not donate sperm during this time.
• If you previously had side effects from immunotherapy drugs, those side effects must have mostly or fully resolved before joining (with an exception for thyroid problems that are well controlled with medication).
• If you have cancer that has spread to the brain, it must have been treated, you must have had no symptoms for at least 14 days, and you must not currently be receiving any treatment for it (such as steroids above a certain dose, surgery, or radiation).

Who may not be able to join:

• People with a history of autoimmune diseases may not be eligible, though some conditions are exceptions, including: vitiligo, certain skin conditions not requiring systemic (whole-body) treatment, a past thyroid condition called Graves' disease (if the thyroid has been in a normal range for more than 4 weeks), thyroid underactivity managed with hormone replacement, hair loss (alopecia), or arthritis managed without whole-body medications.
• People who have had major surgery or a serious injury within 3 weeks before the first dose of the study drug.
• People who have wounds from surgery or injury that have not yet healed.
• People who have taken steroid medications (such as prednisone) at doses above 10 mg per day, or other immune-suppressing drugs, within 7 days before starting the study drug (note: steroid creams, eye drops, inhalers, or nasal sprays are allowed).
• People who have not yet recovered from the side effects of previous cancer treatments (such as chemotherapy or radiation therapy).
• People who had serious harmful reactions during previous treatment with a drug called IL-2, including events such as bowel perforation, internal bleeding, heart problems, or repeated seizures.
• People who have had an ongoing inflammatory condition (such as inflammation) lasting 4 weeks or more, or a chronic low-grade inflammation such as lung inflammation caused by radiation, regardless of how long it has been present.
• People who have a second, separate cancer that has not been in remission for at least 1 year — though some exceptions apply, such as certain skin cancers, early-stage cervical changes, low-risk localised prostate cancer, or cancers that have never needed treatment (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.